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Abstract
Background: Only 10-15% of smokers develop chronic obstructive pulmonary disease (COPD) which indicates
genetic susceptibility to the disease. Recent studies suggested an association between COPD and polymorphisms
in CHRNA coding subunits of nicotinic acetylcholine receptor. Herein, we performed a meta-analysis to clarify the
impact of CHRNA variants on COPD.
Methods: We searched Web of Knowledge and Medline from 1990 through June 2011 for COPD gene studies
reporting variants on CHRNA. Pooled odds ratios (ORs) were calculated using the major allele or genotype as
reference group.
Results: Among seven reported variants in CHRNA, rs1051730 was finally analyzed with sufficient studies. Totally
3460 COPD and 11437 controls from 7 individual studies were pooled-analyzed. A-allele of rs1051730 was
associated with an increased risk of COPD regardless of smoking exposure (pooled OR = 1.26, 95% CI 1.18-1.34, p <
10
-5). At the genotypic level, the ORs gradually increased per A-allele (OR = 1.27 and 1.50 for GA and AA
respectively, p < 10
-5). Besides, AA genotype exhibited an association with reduced FEV1% predicted (mean
difference 3.51%, 95%CI 0.87-6.16%, p = 0.009) and increased risk of emphysema (OR 1.93, 95%CI 1.29-2.90, p =
0.001).
Conclusions: Our findings suggest that rs1051730 in CHRNA is a susceptibility variant for COPD, in terms of both
airway obstruction and parenchyma destruction.
Keywords: Chronic Obstructive Pulmonary Disease (COPD), Nicotine acetylcholine receptor (nAChR), CHRNA -; , Sin-
gle nucleotide polymorphism (SNP)
Background
Chronic obstructive pulmonary disease (COPD) is one
of the leading causes of morbidity and mortality world-
wide and results in an economic and social burden
which is both substantial and still increasing [1]. It is
characterized by chronic inflammation and irreversible
airflow obstruction which involves structural changes of
the lung [2]. Cigarette smoking is the major risk factor
for the development of COPD [1]. The chronic inflam-
matory process induced by tobacco smoking promotes
the structural changes in the small airways and
parenchyma [2]. Although COPD is regarded as a con-
sequence of smoking, however, only 10-15% of long-
term smokers develop symptomatic airflow obstruction
[1,3,4]. This indicates that the genetic factors might con-
tribute to the individual susceptibility. Family studies,
case-control studies and the recent hypothesis-free gen-
ome-wide association (GWA) studies all support the
role of genetic disposition in the development of COPD
[5-7].
Several single nucleotide polymorphisms (SNPs) in the
gene cluster CHRNA3-CHRNB4-CHRNA5 on chromo-
some 15q25 have been identified to be associated with
nicotine dependence [8-14]. These SNPs are rs1051730,
rs16969968, rs578776, rs8034191, rs588765, rs12914008,
and rs931794. The CHRNA3-CHRNB4-CHRNA5 region
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receptor (nAChR), which are expressed not only in neu-
rons but also in other tissues [15]. These receptors play
an important role in the lung. They are expressed on
structural cells such as bronchial and alveolar epithelial
cells [15-17]; and inflammatory cells such as mast cells,
neutrophils, monocytes and lymphocytes [18]. Experi-
ments of lung cancer cell line and murine models sug-
gested that pulmonary nAChR might serve as a
regulator of proliferation and apoptosis to carcinogens
[19,20]. Moreover, the a5 subunit of the nAChR may be
involved in modifying the inflammatory response to
smoking [21]. The variants in CHRNA have been
reported to be related to functional consequences, such
as altered receptor response to nicotine agonist [15] and
altered mRNA levels of CHRNA5 in brain and lung tis-
sue [22]. Therefore, these variants might cause biological
changes in lung, and contributes to the abnormal
responses to smoking stimuli observed in COPD
patients. Recent studies, especially results from GWA
studies, supported the assumption that this genetic
locus is also associated with COPD [6,23-29].
In order to confirm a conclusive relationship between
genetic locus and susceptibility to COPD, it is important
to determine its impact on the development of COPD
and COPD-related phenotypes. Individual studies on the
association between nAChR polymorphisms and COPD
were of limited sample size and there has been a lack of
replication between various studies. From the most
recent studies focusing on the association between
genetic polymorphisms in 15q25 locus and different
subtypes of COPD (airway obstruction and emphysema)
[24,25], we summarized the current evidence of variants
in CHRNA. We also performed a meta-analysis on pub-
lished case-control studies aiming to confirm the effect
of nAChR variants on susceptibility to COPD.
Methods
Literature search
Literature search was carried out using electronic data-
bases Web of Knowledge (1990 to June 2011) via library
of Fudan University and Medline (1990 to June 2011) by
PubMed search engines, with the databases being last
assessed on 10 July 2011. The search histories were as
follows: (variant OR variation OR genotype OR allele
OR polymorphism OR SNP OR single nucleotide poly-
morphism OR linkage disequilibrium OR haplotype)
AND (nicotinic acetylcholine receptor OR nAChR OR
CHRNA OR cholinergic receptor nicotinic alpha OR
cholinergic nicotinic receptor OR cholinergic receptor
OR nicotinic ACh receptor OR nicotinic receptor OR
15q25 OR 15q24/25 OR 15q24-25 OR rs1051730 OR
rs16969968 OR rs578776 OR rs8034191 OR rs588765
OR rs12914008 OR rs931794) AND (chronic bronchitis
OR emphysema OR chronic obstructive pulmonary dis-
ease OR COPD). The reference lists of relevant publica-
tions were manually searched for additional studies.
Ethical approval was not required for this meta-
analysis.
Study eligibility and data extraction
Studies were included if they reported the genotype
count or allele frequency. The included studies should
be a case-control design, with at least two comparison
g r o u p s ,i . e .C O P Da n dc o n t r o l s .P o p u l a t i o n - b a s e ds t u -
dies were included, but studies base on family or sibling
pairs were excluded. Self-reported COPD were not
acceptable as a reliable diagnosis, and therefore studies
using such diagnostic criteria were excluded. In case of
studies containing the same data sets as studies that had
been published before, only the study with the largest
sample size was included. Data published only in
abstract form or from web-site materials were excluded
due to the fact that these studies had not undergone
peer-review and the inclusion of these studies might
introduce bias into the meta-analysis. Case reports,
review articles, and textbook chapters were also
excluded from the analysis. Two authors independently
reviewed the abstracts of all the studies generated by the
literature search. The variants, which were reported by
more than 5 independent studies, were further meta-
analyzed. The full text articles of all eligible abstracts
were reviewed and data were extracted by the two
authors. Any discrepancies were resolved by discussion
with a third author to reach a final consensus.
The extracted data included: (1) publication details
including year of publication, title, name of the first
author, and country in which the study was conducted;
(2) type of study design; (3) sample size; (4) age range,
gender and ethnicity of the study population; (5) COPD
definition; (6) smoking history of the studied subjects;
(7) allele frequency; (8) genotype counts; (9) phenotypes
(bronchial obstruction and/or emphysema); (10) meth-
ods which were used to investigate polymorphisms. The
authors of the included studies were contacted for addi-
tional information if there was no sufficient data for
analysis.
Data analysis
A methodological meta-analysis was conducted to deter-
mine the overall association between the candidate var-
iant in CHRNA and COPD. Data from each case-control
study were extracted to construct a two-by-two table in
which subjects were classified by diagnostic category
(COPD versus control) and different genotype or alleles.
The odds ratios (ORs) were estimated using the major
allele or genotype as the reference group. All the statisti-
cal analysis was performed by Review Manager Software
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square test was used to evaluate the presence of statisti-
cally significant heterogeneity across the studies and the
inconsistency index (I
2) was used to quantify the
amount of heterogeneity [30]. If there was no heteroge-
neity between studies, a fixed-effect model was used.
Otherwise, a random-effect model was used. The signifi-
cance of the pooled OR was determined by the Z test,
along with 95% confidence intervals (CI). The presence
of publication bias was tested using funnel plots. A p
value <0.05 was considered as statistically significance.
Results
Description of studies
The initial literature search revealed 29 articles, of which
20 were excluded because their title and abstract were
irrelevant to our study question. For all the known var-
iants on 15q25, only rs1051730 was reported by more
than 5 independent studies. In the subsequent literature
analysis, eleven potentially eligible studies on rs1051730
were identified from the remaining 7 articles [23-29].
The study by Wang et al [29] was excluded because the
approach to define COPD was self-reported emphysema
rather than spirometer-based criteria. In the Copenha-
gen City Heart Study, the diagnosis of COPD was based
on the ICD coding in the national Danish Cancer,
Patient and Death registry [23]. The diagnosis was
regarded as reliable because it was registered after hos-
pitalization or outpatient visits. The study by Siedinski
et al [28] was excluded because it was a case-only study.
T h eI C G Ns t u d ya n dt h eB o s t o nE a r l yO n s e tC O P D
study were family-based analysis, and were also excluded
[26]. Finally a total of 7 individual studies from 5 articles
met our inclusion criteria. Figure 1 shows the study
selection process. In the study by Young et al [27], there
were 2 case groups (COPD and lung cancer) and one
control group (healthy volunteers). The authors
compared COPD group with healthy controls, and with
non-COPD subjects including healthy controls and
patients in lung cancer group without COPD, respec-
tively. Considering the overlap of the frequencies of
acetylcholine nicotinic receptor variants between lung
cancer and COPD, the data of comparison between
COPD and primary healthy controls was included into
the current pooled analysis. Therefore, totally 14897
subjects were included in the current analysis, including
3460 COPD and 11437 controls. Table 1 and 2 sum-
marizes the main characteristics of the 7 included stu-
dies. These studies were published between 2008 and
2011.
Association between rs1051730 and COPD
Data from seven independent studies were analyzed for
the OR of A-allele using the G-allele as the reference
group [23-27]. As the statistical heterogeneity and
inconsistency were not found between studies (p = 0.40,
c2 = 6.25, I
2 = 4%), a fix-effect model was used for the
analysis. The A-allele was significantly more common in
COPD subjects compared with control subjects. As
s h o w ni nF i g u r e2 ,t h ep o o l e dO Ro fA - a l l e l ew a s
increased to 1.26 (95% CI 1.18-1.34, p < 10
-5). There-
fore, the A-allele carriers were more susceptible to hav-
ing COPD.
According to the comparability of smoking exposure
(pack-years) between COPD group and control group,
we performed a subgroup analysis. As shown in Table 2,
the numbers of pack-years were comparable between
COPD group and control group in COPACETIC and
LEUVEN cohort. The ORs of both subgroup analyses
were similar to the overall estimate (Table 3). Besides,
we performed pooled-analysis for 3 included studies in
which detailed smoking exposure data were provided,
and no associations were observed in terms of smoking
amount (pack-years), smoking duration (years) or cur-
rent smoking status (data not shown).
Six studies reported the genotype counts. There was
no heterogeneity between studies (for all the compari-
sons, p > 0.05), and analysis was performed under a fix-
effect model. At the genotypic level, homozygous AA
and heterozygous GA carriers exhibited an increased
risk of having COPD compared to homozygous GG car-
riers (Table 4).
The funnel plot for the OR analysis of the frequencies
of A-allele and G-allele between COPD and control
(Figure 3) suggests symmetry, indicating no evidence of
publication bias.
The rs1051730 A-allele carriers showed a reduced lung
function
COPD is a disease characterized with irreversible airflow
obstruction which is confirmed by sprirometry.
Figure 1 Study selection process. COPD, chronic obstructive
pulmonary disease.
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association between SNP rs1051730 and airway obstruc-
tion. Three studies presented forced expiratory volume
in 1 second (FEV1) values against different genotypes.
FEV1% predicted values in GA and AA genotype were
significantly reduced compared to that in GG genotype,
with the mean difference being 3.51% and 6.86% respec-
tively (Figure 4).
Association between SNP rs1051730 and emphysema
Emphysema is a major pathological change in patients
with COPD, indicating tissue destruction. As shown in
Table 5, carriers of A-allele had a higher susceptibility
for emphysema (OR 1.39, 95%CI 1.16-1.68, p = 0.0005).
Similarly, AA and GA genotype both showed an
increased risk for emphysema compared to GG geno-
type. The ORs gradually increased per A-allele (OR
1.37, p = 0.02 and OR 1.93, p = 0.001). Because the
definition of emphysema was inconsistent in various stu-
dies, the number of subjects included in the pooled-ana-
lysis was small, but the associations were still
statistically significant.
Discussion
Genetic findings suggest that COPD is associated with
the chromosome 15q25 region, which includes the
CHRNA5-CHRNA3-CHRNB4 cluster of cholinergic nico-
tinic receptor subunit genes [6,12,15,23-29]. Our study
only focused on the available case-control COPD studies
for this region, and it is the most comprehensive meta-
analysis to date on COPD and nAChR genetic suscept-
ibility. We performed both allele-based and genotype-
based comparisons. We also had data from the most
recent published GWA studies (Bergen and COPACETI
cohort [25,26]). Of 7 reported variants in CHRNA,w e
identified rs1051730 with an adequate number of studies
Table 1 Characteristics of studies included in the meta-analysis.
Study and reference Ethnicity/Country Age COPD definition Smoking history Methodology of
genotyping
Bergen cohort from Pillai et al
[26]
NR/Norway NR post-bronchodilator FEV1<80%
predicted and FEV1/FVC<0.7
a minimum smoking
history of 2.5 pack-years
Illumina’s
HumanHap550
BeadChip
Copenhagen City Heart Study
from Kaur-Knudsen et al [25]
NR/Denmark NR ICD-8 491-492 ICD-10 J41-J44 NR TaqMan method
COPDGene study from Kim et
al [24]
non-Hispanic
white subjects/
America
45-80 post-bronchodilator FEV1<80%
predicted and FEV1/FVC<0.7
a minimum smoking
history of 10 pack-years
TaqMan method
COPACETIC cohort from
Lambrechts et al [23]
NR/the
Netherlands
50-75 pre-bronchodilator FEV1/
FVC<0.7
a minimum smoking
history of 20 pack-years
Illumina’s
HumanHap610-
Quad BeadChip
LEUVEN cohort from
Lambrechts et al [25]
NR/Belgium >50 post-bronchodilator FEV1/
FVC<0.7
a minimum smoking
history of 15 pack-years
iPLEX™ genotyping
assay
NETT/NAS cohorts from Pillai
et al [26]
non-Hispanic
white subjects/
America
NR FEV1 ≤45% predicted and
bilateral emphysema on chest
CT
cases: former smokers
controls: a minimum
smoking history of 10
pack-years
Sequenom iPLEX or
TaqMan method
New Zealand study from
Young et al [27]
Caucasian/New
Zealand
Case: >40;
Controls:45-
80
post-bronchodilator FEV1<80%
predicted and FEV1/FVC<0.7
a minimum smoking
history of 15 pack-years
iPLEX™ genotyping
assay
Abbreviations: NR, not reported; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity
Table 2 Smoking amounts of COPDs and controls in the included studies.
Study and reference Pack-years of smoking
Controls (N) COPDs (N)
Bergen cohort from Pillai et al [26] 19 ± 13*(810) 32 ± 19*(823)
Copenhagen City Heart Study from Kaur-Knudsen et al [25] NR NR
COPDGene study from Kim et al [24] 52 ± 29*(335) 37 ± 19*(507)
COPACETIC cohort from Lambrechts et al [23] 38.0 (28.0-46.2) (295) 38.7 (29.7-49.5)(161)
LEUVEN cohort from Lambrechts et al [25] 42.3 (30.0-50.5) (184) 40.0 (30.0-57.0) (475)
NETT/NAS cohorts from Pillai et al [26] 40 ± 28*(472) 66 ± 30*(389)
New Zealand study from Young et al [27] 40 ± 19*(488) 47 ± 20*(458)
Abbreviations: Data were presented as median (25th - 75th percentiles) for COPACETIC and LEUVEN cohorts, and as mean ± SD for other studies. NR, not
reported; COPD, chronic obstructive pulmonary disease, defined by spirometric results; * p < 0.05
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rs1051730 was significantly associated with a risk of
having COPD (OR 1.26, 95%CI 1.18-1.34, p < 10
-5). In
addition, AA genotype, compared to GG genotype,
showed statistically significant evidence of association
with lower FEV1% predicted (mean difference 3.51%,
95%CI 0.87-6.16%, p = 0.009) and higher incidence of
emphysema (OR 1.93, 95%CI 1.29-2.90, p = 0.001).
There was limited data about the association between
the susceptibility to COPD and other variants in
CHRNA. In the COPD GWA study, rs16969968 (which
is in strong linkage disequilibrium with rs1051730)
showed a weaker association than rs1051730 [26]. In the
same GWA study, rs8034191 was related to a higher
risk of having COPD. An association between rs8034191
and FEV1 in emphysema was observed in individual stu-
dies [24,26]. In a recently published meta-analysis with
the primary objective to identify the variants affecting
smoking quantity in chromosome 15q25, 3 data sets
with COPD trait were used to analysis the relationship
between COPD and rs16969968, rs588765, and
rs578776, but only rs16969968 showed a suggestive
association [12].
The overlap of nAChR polymorphisms for nicotine
dependence and COPD has led to the debate whether
polymorphisms in CHRNA have a direct effect on
COPD or merely mediate smoking habits [8,15,27].
Saccone et al [12] reported a weak association between
rs16969968 and COPD (OR 1.12, 95%CI 1.01-1.23, p =
0.01) after adjusting for cigarettes-per-day, and the esti-
mate was lower than that for cigarettes-per-day. How-
ever, the analysis of Saccone et al [12] included self-
reported COPD and chronic bronchitis, and this might
weaken the association between SNPs and COPD.
Results of the current study indicated a stronger associa-
tion between SNP rs1051730 and spirometer-confirmed
COPD, and SNP rs1051730 directly impacts the devel-
opment of COPD. ORs of SNP rs1051730 for COPD
were increased whether the smoking amount was com-
parable between COPD and control group or not,
although the statistical power was stronger when the
smoking exposure amount was larger in COPD group
than control group (Table 3).
The acetylcholine receptors are expressed throughout
the lung and mediate the direct effects of nicotine [31].
Besides regulating cholinergic activities in the airways,
recent studies demonstrated that they also played a role
in cellular proliferation and inflammatory response in
the lung [18,32]. Therefore the nAChRs could not only
be correlated to smoking traits such as cigarettes-per-
day and smoking addition, but also could be related to
other biological effects. Polymorphism of rs1051730 in
15q25 locus represents a synonymous G to A nucleotide
exchange in the CHRNA3 gene. The genetic variant was
Figure 2 Forest plot of the pooled ORs for COPD comparing rs1051730 A-allele with G-allele. The circles in squares and the horizontal
lines represent the point estimate and 95% CI, respectively, for each included study; the diamond shape represents the pooled estimate and
95% CI. OR, odds ratio; COPD, chronic obstructive pulmonary disease; CI, confidence interval; df, degree of freedom.
Table 3 Association between rs1051730 A-allele and COPD
Smoking amount Number of subjects A-allele vs G-allele effect Heterogeneity
Control COPD OR (95%CI) Z p Chi
2 pI
2 (%)
comparable 479 636 1.29 (1.07- 1.55) 2.62 0.009 1.34 0.25 25
incomparable 2105 2177 1.35 (1.22- 1.48) 6.12 <10
-5 0.77 0.86 0
Subgroup analysis was performed according to the comparability of smoking amount between COPD and control group of included studies. Abbreviations:
COPD, chronic obstructive pulmonary disease; CI, confidence interval.
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[11]. At the same time, SNP rs1051730 is in linkage dis-
equilibrium with rs16969968, which changes an amino
acid (D398N) in alpha5 nicotinic receptor subunits and
alters receptor function [15]. These two genetic variants
in CHRNA3/5 gene cluster might work together and
alter the function of nicotinic receptor in lung tissue
and further increase the risk for COPD. Our findings
showed that SNP rs1051730 was associated with a
reduced FEV1 (Figure 4), and this might be explained by
the increase in airway contraction and mucus secretion
due to the altered receptor function. An association was
also observed with the presence of emphysema (Table
5). In another study, rs1051730 was reported to be asso-
ciated with emphysema severity in ex-smokers [24]. The
data was not included into the current pooled-analysis,
because the emphysema severity was expressed in quan-
titive CT values and the genotype counting was not
available. It is plausible that the alteration in peripheral
nicotinic receptors might have an impact on tobacco
induced tissue destruction. To confirm the direct effect
of rs1051730 on COPD, further investigation is needed
to measure the mRNA and protein expressions of
nAChRs subunits in COPD lungs, as well as the impact
of SNP rs1051730 on the functional alterations and its
role in the development of COPD and in different sub-
types of COPD.
COPD is a multi-factorial disease, and therefore, a
variety of genes in the biological pathway of COPD
might act together in the development and progression
of the disease, and single polymorphism might have
interactions with other genetic factors. Apart from SER-
PINA1 gene encoding the alpha-1 antitrypsin protein
[33,34], a series of genetic factors other than nAChR
variants have been identified to influence susceptibility
to COPD in 6 previous meta-analysis [5,7,35-38]. These
polymorphisms were the Tyr113His and His139Arg in
EPHX1, IL1RN variable number tandem repeat (VNTR)
polymorphism, the GSTM1 null variant, Ile105Val
(rs1695) in GSTP1, rs2241712/rs1982073/rs6957/
rs1800470 in TGFB1, 308GA (rs1800629) in TNF and
rs1799896 in SOD3. Furthermore, another gene IREB2
was also identified as a potential gene for COPD sus-
ceptibility [39,40]. IREB2 and CHRNA are both on chro-
mosome 15q25. It was found that IREB2 protein and
mRNA were increased in lung-tissue samples from
COPD subjects in comparison to controls. However,
further investigations are essentially required in order to
understand more about the interaction between
rs1051730 and other genes (such as IREB2)f o rt h e
pathogenesis of COPD in the future.
Our study has the following limitations. First, our
study did not consider gene-by-smoking interactions. In
all included studies except the Copenhagen City Heart
Study, inclusion criteria on smoking history was similar
in case and control group (Table 1); however, the smok-
i n ga m o u n tw e r ec o m p a r a b l eo n l yi nC O P A C E T I C
cohort and LEUVEN cohort (Table 2). Given the impor-
tance of smoking in the development of COPD and the
known association between nAChR variants and smok-
ing behavior[11,12,15], future studies with equivalent
smoking exposure in case and control subjects are
required to address this limitation. Second, we only ana-
lyzed part of data of COPACETIC GWA study because
the full set of results was not available. Third, the ima-
ging protocols in the detection of emphysema are differ-
ent in various studies. The number of studies for
emphysema is therefore insufficient, because the hetero-
geneity of the calculating methods for emphysema
severity. Fourth, all the subjects in the current meta-
analysis are European-descendants. Future studies in
Asian and African populations would help to determine
the ethnic differences of the relationship between
rs1051730 and COPD. Finally, publication bias might
have influenced some of our results. Exclusion of case-
Table 4 Association between rs1051730 genotypes and COPD
Genotype Number of subjects Overall effect Heterogeneity
COPD Total OR (95%CI) Z p Chi
2 pI
2 (%)
GA/GG 1432/1201 6227/6188 1.27 (1.15- 1.40) 4.81 <10
-5 7.71 0.17 35
AA/GG 438/1201 1621/6188 1.50 (1.30- 1.73) 5.51 <10
-5 2.02 0.85 0
Abbreviations: COPD, chronic obstructive pulmonary disease; CI, confidence interval.
Figure 3 Funnel plot for the assessment of potential
publication bias in rs1051730 variant frequencies. SE, standard
error; OR, odds ratio; COPD, chronic obstructive pulmonary disease.
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have contributed to publication bias. Usually, studies
with positive results have a greater chance to be pub-
lished and studies with inconsistent results of associa-
tion are usually not published, thus these can potentially
increase publication bias in our analysis.
In summary, quantitative meta-analysis identified
rs1051730 in CHRNA as a susceptibility variant for the
development of COPD, in terms of both airway obstruc-
tion and parenchyma destruction. A-allele carriers have
a higher risk for COPD, and have a lower FEV1%pre-
dicted and higher incidence of emphysema. However,
many questions are still to be answered before establish-
ing nAChRs as an interventional target for COPD. Epi-
demiologic analysis in different ethnic populations, the
mediating effect of smoking exposure, and functional
studies should be prioritized for further research.
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